Samsung Electronics Switzerland has teamed up with Bottneuro AG, a Swiss MedTech startup, to develop an innovative solution for the diagnosis and treatment of Alzheimer’s disease. The technology uses 3D magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging data to identify affected areas of the brain, which can then be targeted and electronically stimulated with Miamind® neurostimulator technology.
This cutting-edge technology is designed to improve the diagnosis and treatment of Alzheimer’s disease, a condition that affects over 50 million people worldwide. Alzheimer’s is a progressive disease that affects the brain, causing memory loss, cognitive decline, and eventually, the inability to perform even basic tasks.
Bottneuro AG’s innovative approach to Alzheimer’s treatment is based on a comprehensive understanding of the disease and its progression. The company’s technology identifies areas of the brain affected by the disease and targets them with Miamind® neurostimulator technology, a non-invasive treatment that has been shown to improve cognitive function in patients.
Samsung Galaxy Tab S8+ 5G Enterprise Edition hardware is used to store and record therapy data in the Bottneuro Solution, making it easier for patients to manage their treatment. The Galaxy Tab S8+ 5G Enterprise Edition has an intuitive interface and usability that is easy for patients to operate and understand.
Patients who suffer from dementia often experience reduced cognitive function in the early stages of the disease, making the need for finding a device that is easy to operate and understand imperative for Bottneuro AG. With its high-resolution Super AMOLED display, the Galaxy Tab S8+ 5G Enterprise Edition provides brilliant clarity for both patients and healthcare providers.
In addition to providing a reliable and safe solution, Samsung Knox can be used to individually configure the Galaxy Tab S8+ 5G Enterprise Edition, keeping sensitive data and medical records private and protected.
“We were looking for a simple and reliable solution for our application. We found it with the Galaxy Tab S8+ 5G Enterprise Edition, and Samsung is giving us great support in the development,” said Julius Klaas, CTO of Bottneuro AG.
The Galaxy Tab S8+ 5G Enterprise Edition is also directly powered by the Miamind® neurostimulator, and once treatment is complete, the device automatically transmits diagnostic and treatment information contained within the Bottneuro solution to Bottneuro AG via 5G data connectivity, allowing patients to stay in the comfort of their own homes.
Samsung has been supporting and working with Bottneuro AG since its founding in 2021. “We are pleased to offer Bottneuro AG a reliable, safe, and simple solution with Samsung Knox and to support their novel therapy approach,” said Daniele Casella, Head of MX B2B Mobile at Samsung Switzerland.
The effectiveness of Bottneuro AG’s new therapeutic treatment will be tested in several clinical studies this year. While the treatment is not commercially available yet, Bottneuro AG and Samsung remain optimistic about the progress that can be made to treat Alzheimer’s disease.
The partnership between Samsung and Bottneuro AG highlights the importance of collaboration and innovation in the healthcare industry. By working together, companies can develop cutting-edge solutions that improve the quality of life for patients and make a real difference in the fight against diseases like Alzheimer’s.
As medical technology continues to evolve and offer the latest solutions and treatments to patients, collaborations like this one between Samsung and Bottneuro AG are critical to advancing the field and providing better care for patients worldwide.